Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Blueprint Medicines beat estimated earnings by 7.73%, reporting an EPS of $-1.79 versus an estimate of $-1.94.
Revenue was up $41.16 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.66 which was followed by a 7.75% drop in the share price the next day.
Here's a look at Blueprint Medicines's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | -1.65 | -1.63 | -1.86 | -1.86 |
| EPS Actual | -0.99 | -2 | -1.86 | -1.72 |
| Revenue Estimate | 102.69M | 42.47M | 19.01M | 17.25M |
| Revenue Actual | 107.02M | 24.19M | 27.30M | 21.58M |
To track all earnings releases for Blueprint Medicines visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
